DelveInsight’s, “CAR-T Therapy Pipeline Insight 2023” report provides comprehensive insights about 200+ CAR-T Therapy companies and 252+ pipeline drugs in the CAR-T Therapy pipeline landscape. It covers the CAR-T Therapy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CAR-T Therapy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the CAR-T Therapy Pipeline Report
- DelveInsight’s CAR-T Therapy pipeline report depicts a robust space with 200+ active players working to develop 252+ pipeline therapies for CAR-T Therapy treatment.
- The leading CAR-T Therapy companies working in the market include CARsgen, CASI Pharmaceuticals, Tessa Therapeutics, Cartesian Therapeutics, Gracell Bio, Aurora BioPharma, Carsgen Therapeutics, Autolus Limited, CRISPR Therapeutics, Allogene Therapeutics, Verismo Therapeutics, Arcellx, Nexcella, JW Therapeutics, Janssen Pharmaceuticals, Chongqing Precision Biotech, CoImmune, Inc., Mustang Bio, Novartis Pharmaceuticals, Shanghai Unicar-Therapy Bio-medicine Technology, Sotio Biotech Inc., Beam Therapeutics, AbCLon, Nanjing IASO Biotherapeutics, Autolus, Beijing Immunochina Medical Science and Technology, Carsgen Therapeutics, Orgenesis, IN8Bio, Oxford BioMedica, and others.
- Promising CAR-T Therapy Pipeline Therapies in the various stages of development include Glofitamab, Obinutuzumab, Tocilizumab, Pembrolizumab, C-CAR066, Mosunetuzumab, Polatuzumab, and others.
- January 2024: Janssen Research & Development LLC announced a study of Phase 2 clinical trials for JNJ-68284528, Lenalidomide, Daratumumab, Bortezomib and Dexamethasone. The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.
- January 2024: CARsgen Therapeutics Co. Ltdannounced a study of Phase 1 & 2 clinical trials for CT041 autologous CAR T-cell injection. This study is an open, multicenter, Phase Ib/II clinical trial evaluating chimeric antigen receptor-modified autologous T cells targeting Claudin18.2 (CLDN18.2) (CT041 autologous CAR T) in subjects with CLDN18.2 expression-positive, advanced gastric/esophagogastric conjugate adenocarcinoma that has failed at least 2 prior lines therapy and advanced pancreatic cancer that has failed at least 1 prior line therapy. The purpose is to evaluate the efficacy, safety and pharmacokinetics There are two stages in the study. Phase Ib stage is dose escalation and dose expansion study, and Phase II stage is to verify the efficacy and safety of CT041 treatment.
- January 2024: Caribou Biosciences Inc. announced a study of Phase 1 clinical trials for CB-011. This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory).
- December 2023: Novartis Pharmaceuticals announced a study of Phase 2 clinical trials for PHE885. A Phase 2 Study of PHE885, B-cell Maturation Antigen (BCMA)- Directed CAR-T Cells in Adult Participants With Relapsed and Refractory Multiple Myeloma.
- December 2023: Allogene Therapeutics announced a study of Phase 1 clinical trials for ALLO-501, ALLO-647, Fludarabine and Cyclophosphamide. The purpose of the ALPHA study is to assess the safety, efficacy, cell kinetics and immunogenicity of ALLO-501 in adults with relapsed or refractory large B-cell lymphoma or follicular lymphoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647.
Request a sample and discover the recent advances in CAR-T Therapy Drugs @ CAR-T Therapy Pipeline Outlook Report
In the CAR-T Therapy Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, CAR-T Therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details. The assessment part of the report embraces, in depth CAR-T Therapy commercial assessment and clinical assessment of the CAR-T Therapy pipeline products under development.
CAR-T Therapy Overview
CAR T cell therapy uses T cells engineered with CARs to treat cancer. The premise of CAR T immunotherapy is to modify T cells to recognize cancer cells to more effectively target and destroy them. Scientists harvest T cells from people, genetically alter them, and then infuse the resulting CAR T cells into patients to attack their tumors. Cancer Immunotherapy utilizes and enhances the immune system’s standard capacity and is considered one of the most promising approaches for treating various diseases (including cancer, autoimmune diseases, and allergic–hypersensitivity reactions) are severe.
Find out more about CAR-T Therapy Analysis @ CAR-T Therapy Drugs
CAR-T Therapy Emerging Drugs Profile
- CT053: Carsgen Therapeutics
- Descartes-08: Cartesian Therapeutics
- ALLO-501A: Allogene Therapeutics
- CTX110: CRISPR Therapeutics
- IMPT 314: ImmPACT Bio
- ALLO-715: Allogene Therapeutics
CAR-T Therapy Therapeutics Assessment
There are approx. 200+ CAR-T Therapy companies which are developing the therapies for CAR-T Therapy. The CAR-T Therapy companies which have their CAR-T Therapy drug candidates in the most advanced stage, i.e. Registered include, Carsgen Therapeutics. The CAR-T Therapy pipeline report proffers an integral view of the emerging CAR-T Therapy segmented by stage, product type, molecule type, and route of administration.
CAR-T Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Dive deep into rich insights for new CAR-T Therapy, visit @ CAR-T Therapy Treatment Landscape
CAR-T Therapy Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Scope of the CAR-T Therapy Pipeline Report
- Coverage- Global
- CAR-T Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- CAR-T Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- CAR-T Therapy Companies- CARsgen, CASI Pharmaceuticals, Tessa Therapeutics, Cartesian Therapeutics, Gracell Bio, Aurora BioPharma, Carsgen Therapeutics, Autolus Limited, CRISPR Therapeutics, Allogene Therapeutics, Verismo Therapeutics, Arcellx, Nexcella, JW Therapeutics, Janssen Pharmaceuticals, Chongqing Precision Biotech, CoImmune, Inc., Mustang Bio, Novartis Pharmaceuticals, Shanghai Unicar-Therapy Bio-medicine Technology, Sotio Biotech Inc., Beam Therapeutics, AbCLon, Nanjing IASO Biotherapeutics, Autolus, Beijing Immunochina Medical Science and Technology, Carsgen Therapeutics, Orgenesis, IN8Bio, Oxford BioMedica, and others.
- CAR-T Therapy Pipeline Therapies- Glofitamab, Obinutuzumab, Tocilizumab, Pembrolizumab, C-CAR066, Mosunetuzumab, Polatuzumab, and others.
For further information on the CAR-T Therapy Pipeline Therapeutics, reach out @ CAR-T Therapy Therapeutics Segmentation
Table of Content
- Introduction
- Executive Summary
- CAR-T Therapy: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- CAR-T Therapy– DelveInsight’s Analytical Perspective
- Late Stage Products (Registered)
- CT053: Carsgen Therapeutics
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Descartes-08: Cartesian Therapeutics
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- ALLO-715: Allogene Therapeutics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- ACLX 003: Arcellx
- Drug profiles in the detailed report…..
- Inactive Products
- CAR-T Therapy Key Companies
- CAR-T Therapy Key Products
- CAR-T Therapy- Unmet Needs
- CAR-T Therapy- Market Drivers and Barriers
- CAR-T Therapy- Future Perspectives and Conclusion
- CAR-T Therapy Analyst Views
- CAR-T Therapy Key Companies
- Appendix
Find out more about CAR-T Therapy Therapeutics Assessment @ CAR-T Therapy Preclinical and Discovery Stage Products
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/mouth-neoplasms-market